semaglutide and nafld Efficacy safety of subcutaneous once-daily versus placebo in patients with nonalcoholic steatohepatitis Semaglutide Resolves NASH in Big Placebo-Controlled Trial Dawn of an era of
Description
Additionally, weekly GLP-1RA users were more adherent to medication but less persistent than daily GLP-1RA users
Bridwell, GLP-1 agonists: A review for emergency clinicians, Am
This usually means waiting a bit longer between doses, not shorter
88.8% of Phase 2 participants on the 12mg dose completed the full 48-week trial
